Drug intelligence / Profile preview

CB901

Development stage: Preclinical
Lead developer: Cascade Biotechnology
Modality: Recombinant Proteins and Enzymes

Overview

CB901 is a complement-targeting biologic being developed by Cascade Biotechnology for the treatment of Amyotrophic Lateral Sclerosis (ALS). The drug candidate is built upon the company's proprietary sC3 (Complement Depleting Protein) platform, which is designed to systematically deplete complement activity to mitigate the neuroinflammatory processes that drive motor neuron loss in ALS. Currently in the early discovery and preclinical stage, CB901 is undergoing in vitro research to establish its therapeutic profile and efficacy in modulating the complement cascade.

Targets

Complement (Complement system)

Beyond the preview

Go deeper on CB901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB901.

Explore the full profile